Challenges and prospects of patient-derived xenografts for cancer research
J Jin, K Yoshimura, M Sewastjanow-Silva, S Song… - Cancers, 2023 - mdpi.com
Simple Summary The patient-derived xenograft (PDX) model is the in vivo standard for
cancer research as a preclinical platform. Besides its merits, we describe the general …
cancer research as a preclinical platform. Besides its merits, we describe the general …
[HTML][HTML] Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
S Al Bitar, M El-Sabban, S Doughan… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …
Standardization of organoid culture in cancer research
C Zhou, Y Wu, Z Wang, Y Liu, J Yu, W Wang… - Cancer …, 2023 - Wiley Online Library
Establishing a valid in vitro model to represent tumor heterogeneity and biology is critical but
challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are …
challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are …
Systematic review: predictive value of organoids in colorectal cancer
BC Sakshaug, E Folkesson, TH Haukaas, T Visnes… - Scientific Reports, 2023 - nature.com
While chemotherapy alone or in combination with radiotherapy and surgery are important
modalities in the treatment of colorectal cancer, their widespread use is not paired with an …
modalities in the treatment of colorectal cancer, their widespread use is not paired with an …
Engineered Human Organoids for Biomedical Applications
Human organoid models potentially offer a physiologically relevant platform to replace
traditional monolayer cultures and animal models. In particular, the rapid development of …
traditional monolayer cultures and animal models. In particular, the rapid development of …
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
LP Smabers, E Wensink, CS Verissimo… - Journal of Experimental …, 2024 - Springer
Background The inability to predict treatment response of colorectal cancer patients results
in unnecessary toxicity, decreased efficacy and survival. Response testing on patient …
in unnecessary toxicity, decreased efficacy and survival. Response testing on patient …
Alternatives of animal models for biomedical research: a comprehensive review of modern approaches
A Vashishat, P Patel, G Das Gupta… - Stem Cell Reviews and …, 2024 - Springer
Biomedical research has long relied on animal models to unravel the intricacies of human
physiology and pathology. However, concerns surrounding ethics, expenses, and inherent …
physiology and pathology. However, concerns surrounding ethics, expenses, and inherent …
The efficacy of using patient-derived organoids to predict treatment response in Colorectal Cancer
C Su, KA Olsen, CE Bond, VLJ Whitehall - Cancers, 2023 - mdpi.com
Simple Summary Colorectal cancer is the third most commonly diagnosed cancer. Patients
may receive chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or surgery …
may receive chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or surgery …
[HTML][HTML] Cancer organoids: A platform in basic and translational research
X Ma, Q Wang, G Li, H Li, S Xu, D Pang - Genes & diseases, 2024 - Elsevier
An accumulation of previous work has established organoids as good preclinical models of
human tumors, facilitating translation from basic research to clinical practice. They are …
human tumors, facilitating translation from basic research to clinical practice. They are …
[HTML][HTML] Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
G Martini, V Belli, S Napolitano, V Ciaramella… - ESMO open, 2023 - Elsevier
Background Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from
molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an …
molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an …